{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-017186","form_type":"8-K","ticker":"OM","cik":"0001484612","company_name":"Outset Medical, Inc.","filed_at":"2023-05-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.004368+00:00","generated_at":"2026-06-16T00:55:46.181010+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Outset Medical Q1 revenue $33.5M (+9.5% YoY); raises FY2023 revenue and margin guidance","bullets":["Revenue $33.5M, up 9.5% YoY; product revenue $27.8M (+8.2%), service revenue $5.7M (+16.4%).","Gross margin 19.2% (20.3% non-GAAP), up from 14.5% a year ago; product margin 25.1% vs 10.0%.","Net loss ($44.0M) or ($0.90) per share; non-GAAP net loss ($35.4M) or ($0.72) per share.","FY2023 revenue guidance raised to $144-$150M (prior $140-$150M); gross margin guidance raised to low-20% (from ~20%).","Added over 30 new hospital sites in Q1, largest quarterly new site growth since 2021; cash $252.5M."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-017186","json":"https://secwatch.observer/filing/0000950170-23-017186.json","markdown":"https://secwatch.observer/filing/0000950170-23-017186.md","text":"https://secwatch.observer/filing/0000950170-23-017186.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1484612/000095017023017186/0000950170-23-017186-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1484612/000095017023017186/om-20230503.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-16T00:55:46.181010+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e940b5b523515ee992bd0b3e2a694b03488cf748","claim":"Outset Medical, Inc. reported first quarter ended March 31, 2023 results: revenue $33.5 million, net income ($44.0) million, EPS ($0.90) per share. Guidance raised.","evidence_excerpt":"to reduce the cost and complexity of dialysis, today reported financial results for the first quarter ended March 31, 2023. Recent Highlights • Recorded net revenue of $33.5 million in the first quarter, a 9.5% increase compared to $30.6 million in the first quarter of 2022, and a 4.6% increase compared to $32.0 million in the fourth quarter of 2022 •","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1484612/000095017023017186/0000950170-23-017186-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2023"},{"label":"Revenue","value":"$33.5 million"},{"label":"Net income","value":"($44.0) million"},{"label":"EPS","value":"($0.90) per share"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}